Patents by Inventor Yuri Nambu
Yuri Nambu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140235822Abstract: The present invention provides a method for producing a peptide, characterized in that it comprises converting an —SH group of a peptide comprising an amino acid residue having the —SH group to an —OH group, wherein said method comprises the following steps (a) to (c): (a) allowing an —SH group in a peptide to react with a methylating agent to convert the —SH group to an -SMe group; (b) allowing the -SMe group obtained in the step (a) to react with a cyanizing agent to produce a reaction intermediate; and (c) converting the reaction intermediate obtained in the step (b) to a peptide comprising an amino acid residue having an —OH group under more basic conditions than the conditions in the step (b).Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicant: Glytech, Inc.Inventors: Yasuhiro Kajihara, Izumi Sakamoto, Yuri Nambu, Kazuhiro Fukae, Hiroaki Asai
-
Patent number: 8809258Abstract: The present invention provides a method for producing a peptide, characterized in that it comprises converting an —SH group of a peptide comprising an amino acid residue having the —SH group to an —OH group, wherein said method comprises the following steps (a) to (c): (a) allowing an —SH group in a peptide to react with a methylating agent to convert the —SH group to an -SMe group; (b) allowing the -SMe group obtained in the step (a) to react with a cyanizing agent to produce a reaction intermediate; and (c) converting the reaction intermediate obtained in the step (b) to a peptide comprising an amino acid residue having an —OH group under more basic conditions than the conditions in the step (b).Type: GrantFiled: July 30, 2008Date of Patent: August 19, 2014Assignee: Glytech, Inc.Inventors: Yasuhiro Kajihara, Izumi Sakamoto, Yuri Nambu, Kazuhiro Fukae, Hiroaki Asai
-
Patent number: 8765669Abstract: Oligosaccharide chain added GLP-1 peptides are more stable in blood and more active in controlling blood-sugar levels than GLP-1 peptides without added oligosaccharides. Oligosaccharide chain added GLP-1 peptides having GLP-1 activity include at least one or at least two amino acids each substituted with an oligosaccharide chain added amino acid in GLP-1; a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or a GLP-1 analog. Oligosaccharide chain added GLP-1 peptides with at least one amino acid substituted with an oligosaccharide chain added amino acid include an oligosaccharide chain with oligo hyaluronic acid. Oligosaccharide chain added amino acids include oligosaccharide chains attached to amino acids via linkers.Type: GrantFiled: June 15, 2009Date of Patent: July 1, 2014Assignee: Glytech, Inc.Inventors: Yasuhiro Kajihara, Takashi Tsuji, Izumi Sakamoto, Yuri Nambu, Naohiro Hayashi, Kazuyuki Ishii, Kazuhiro Fukae, Katsunari Tezuka, Hiroaki Asai
-
Publication number: 20130345129Abstract: The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.Type: ApplicationFiled: June 7, 2013Publication date: December 26, 2013Applicant: GLYTECH, INC.Inventors: YASUHIRO KAJIHARA, TAKASHI TSUJI, IZUMI SAKAMOTO, YURI NAMBU, KAZUHIRO FUKAE, KATSUNARI TEZUKA, HIROAKI ASAI
-
Patent number: 8507429Abstract: The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.Type: GrantFiled: June 2, 2011Date of Patent: August 13, 2013Assignee: Glytech, Inc.Inventors: Yasuhiro Kajihara, Takashi Tsuji, Izumi Sakamoto, Yuri Nambu, Kazuhiro Fukae, Katsunari Tezuka, Hiroaki Asai
-
Publication number: 20120264684Abstract: Disclosed is a glucagon-like peptide-1 (GLP-1) analogue which is obtained by ameliorating a highly antigenic GLP-1 analogue so that the GLP-1 analogue has reduced antigenicity without being lowered in the blood glucose suppressing activity. Specifically disclosed is a glycosylated form of an antigenic GLP-1 analogue, which has GLP-1 activity and is obtained by substituting at least one amino acid of an antigenic GLP-1 analogue with a glycosylated amino acid.Type: ApplicationFiled: October 25, 2010Publication date: October 18, 2012Inventors: Yasuhiro Kajihara, Takashi Tsuji, Yuri Nambu, Kazuyuki Ishii, Kenta Yoshida, Katsunari Tezuka
-
Publication number: 20120047586Abstract: Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function.Type: ApplicationFiled: October 23, 2008Publication date: February 23, 2012Applicant: Otsuka Chemical Co., LtdInventors: Takashi Tsuji, Yasuhiro Kajihara, Katsunari Tezuka, Yuri Nambu, Kazuhiro Fukae, Hiroaki Asai
-
Patent number: 8058394Abstract: The present invention provides a process for producing a peptide thioester compound. The process involves: (A) forming a peptide by a solid-phase synthesis method using a resin modified with a linker represented by the formula (1) as a solid phase: wherein R1 represents C1-4 alkyl group, R2 represents hydrogen atom or C1-4 alkoxy group, and n represents an integer of 1 to 4; (B) cleaving a bond between the solid phase and the peptide with at least one acid selected from dilute hydrochloric acid, dilute sulfuric acid, formic acid, and acetic acid to produce a peptide having a carboxyl group at the C-terminus; and (C) reacting a thiol compound with the peptide at ?100 to 0° C. in the presence of a condensing agent in a solvent.Type: GrantFiled: March 28, 2007Date of Patent: November 15, 2011Assignee: Otsuka Chemical Co., Ltd.Inventors: Yasuhiro Kajihara, Naoki Yamamoto, Yuri Nambu, Kazuhiro Fukae, Hiroaki Asai
-
Publication number: 20110245166Abstract: The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.Type: ApplicationFiled: June 2, 2011Publication date: October 6, 2011Applicant: OTSUKA CHEMICAL HOLDINGS CO., LTDInventors: Yasuhiro KAJIHARA, Takashi TSUJI, Izumi SAKAMOTO, Yuri NAMBU, Kazuhiro FUKAE, Katsunari TEZUKA, Hiroaki ASAI
-
Publication number: 20110195897Abstract: Oligosaccharide chain added GLP-1 peptides are more stable in blood and more active in controlling blood-sugar levels than GLP-1 peptides without added oligosaccharides. Oligosaccharide chain added GLP-1 peptides having GLP-1 activity include at least one or at least two amino acids each substituted with an oligosaccharide chain added amino acid in GLP-1; a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or a GLP-1 analog. Oligosaccharide chain added GLP-1 peptides with at least one amino acid substituted with an oligosaccharide chain added amino acid include an oligosaccharide chain with oligo hyaluronic acid. Oligosaccharide chain added amino acids include oligosaccharide chains attached to amino acids via linkers.Type: ApplicationFiled: June 15, 2009Publication date: August 11, 2011Applicant: OTSUKA CHEMICAL CO., LTD.Inventors: Yasuhiro Kajihara, Takashi Tsuji, Izumi Sakamoto, Yuri Nambu, Naohiro Hayashi, Kazuyuki Ishii, Kazuhiro Fukae, Katsunari Tezuka, Hiroaki Asai
-
Patent number: 7985731Abstract: The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.Type: GrantFiled: June 17, 2008Date of Patent: July 26, 2011Assignee: Otsuka Chemical Holdings Co., Ltd.Inventors: Yasuhiro Kajihara, Takashi Tsuji, Izumi Sakamoto, Yuri Nambu, Kazuhiro Fukae, Katsunari Tezuka, Hiroaki Asai
-
Publication number: 20110172392Abstract: The present invention provides a method for producing a peptide, characterized in that it comprises converting an —SH group of a peptide comprising an amino acid residue having the —SH group to an —OH group, wherein said method comprises the following steps (a) to (c): (a) allowing an —SH group in a peptide to react with a methylating agent to convert the —SH group to an —SMe group; (b) allowing the —SMe group obtained in the step (a) to react with a cyanizing agent to produce a reaction intermediate; and (c) converting the reaction intermediate obtained in the step (b) to a peptide comprising an amino acid residue having an —OH group under more basic conditions than the conditions in the step (b).Type: ApplicationFiled: July 30, 2008Publication date: July 14, 2011Applicant: OTSUKA CHEMICAL CO., LTD.Inventors: Yasuhiro Kajihara, Izumi Sakamoto, Yuri Nambu, Kazuhiro Fukae, Hiroaki Asai
-
Publication number: 20100306864Abstract: Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function.Type: ApplicationFiled: October 23, 2008Publication date: December 2, 2010Applicant: Otsuka Chemical Co., LtdInventors: Takashi Tsuji, Yasuhiro Kajihara, Katsunari Tezuka, Yuri Nambu, Kazuhiro Fukae, Hiroaki Asai
-
Publication number: 20100080794Abstract: Mutant polypeptides of the present invention contain an Fc region in which a cysteine residue is substituted for the second amino acid from the glycosylation site to the N terminal side in the Fc region. The Fc region is preferably a human IgG Fc region. The mutant polypeptides of the present invention may also contain an N-linked sugar chain at the glycosylation site in Fc region. Furthermore, a polypeptide domain other than the Fc region of the mutant polypeptides of the present invention may be a polypeptide molecule that recognizes a human cell surface molecule.Type: ApplicationFiled: April 12, 2007Publication date: April 1, 2010Inventors: Takashi Tsuji, Yasuhiro Kajihara, Yuri Nambu, Kazuhiro Fukae, Hiroaki Asai, Akihiro Murakami
-
Publication number: 20090137780Abstract: The present invention provides a process for producing a peptide thioester compound, characterized by comprising: (A) forming a peptide by a solid-phase synthesis method using a resin modified with a linker represented by the formula (1) as a solid phase; (B) cleaving a bond between the solid phase and the peptide with at least one acid selected from dilute hydrochloric acid, dilute sulfuric acid, formic acid, and acetic acid to produce a peptide having a carboxyl group at the C-terminus; and (C) reacting a thiol compound with the peptide at ?100 to 0° C. in the presence of a condensing agent in a solvent: (1) wherein R1 represents C1-4 alkyl group, R2 represents hydrogen atom or C1-4 alkoxy group, and n represents an integer of 1 to 4.Type: ApplicationFiled: March 28, 2007Publication date: May 28, 2009Applicant: OTSUKA CHEMICAL CO., LTD.Inventors: Yasuhiro Kajihara, Naoki Yamamoto, Yuri Nambu, Kazuhiro Fukae, Hiroaki Asai
-
Publication number: 20090111739Abstract: The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.Type: ApplicationFiled: June 17, 2008Publication date: April 30, 2009Applicant: OTSUKA CHEMICAL CO., LTD.Inventors: Yasuhiro Kajihara, Takashi Tsuji, Izumi Sakamoto, Yuri Nambu, Kazuhiro Fukae, Katsunari Tezuka, Hiroaki Asai